Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Phase of Trial: Phase II
Latest Information Update: 01 Jun 2018
At a glance
- Drugs Nelipepimut-S (Primary) ; Sargramostim; Trastuzumab
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 01 Jun 2018 According to a Galena Biopharma media release, data from this study has been submitted for presentation at a major medical conference that will take place during the second half of 2018.
- 01 Jun 2018 Status changed from active, no longer recruiting to discontinued, according to the Sellas Life Sciences Group media release.
- 02 Apr 2018 Interim data presented in a Sellas Life Sciences Group Media Release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History